Summary

The Global Enzymatic DNA Synthesis Market is valued at approximately USD 0.23 billion in 2023 and is projected to register a robust CAGR of 26.40% over the forecast period 2024-2032. Enzymatic DNA synthesis (EDS), a next-generation approach to constructing oligonucleotides and genes, is redefining the pace, precision, and sustainability of synthetic biology workflows. By harnessing enzymes to assemble DNA in vitro, this innovative technology circumvents the limitations of traditional phosphoramidite chemistry, enabling rapid, scalable, and eco-conscious synthesis of longer DNA sequences with reduced error rates. The rising importance of EDS in accelerating advancements across sectors such as personalized therapeutics, agriculture, and biomanufacturing underscores its transformative role in modern life sciences. As the biological sciences gravitate toward automation, modularity, and high-fidelity systems, enzymatic synthesis is poised to become the backbone of next-generation genomic manufacturing.
The exponential growth trajectory of the enzymatic DNA synthesis market is driven by an expanding array of applications in synthetic biology, genetic engineering, and pharmaceutical research. The surging need for synthetic genes, particularly for the development of vaccines, diagnostics, and genetically engineered cell therapies, is amplifying the demand for cost-effective, environmentally benign, and scalable DNA synthesis platforms. EDS technology offers compelling advantages, such as faster turnaround times, room-temperature operations, and the potential for in situ synthesis. Despite its promising outlook, however, the market faces hurdles related to high initial costs, limited commercial scalability compared to conventional methods, and technical challenges in maintaining sequence accuracy over longer DNA constructs.
Within the market, oligonucleotide synthesis continues to command a significant share due to its essential role in CRISPR editing, diagnostics, and gene expression studies. Simultaneously, gene synthesis is rapidly gaining traction as researchers seek turnkey solutions for building entire genetic circuits and metabolic pathways. This growing preference for bespoke, application-driven synthesis services is reshaping vendor strategies, with industry leaders racing to develop enzyme-based synthesis kits and platform-as-a-service (PaaS) models. Furthermore, end-use dynamics reveal a broadening customer base, from academic research institutions and biotechnology companies to government labs and industrial biomanufacturers that demand precision, scale, and sustainability.
The proliferation of enzymatic DNA synthesis is further catalyzed by a global shift toward precision biology, where the ability to write and rewrite DNA at will enables breakthroughs in fields ranging from gene therapy to agrigenomics. In synthetic biology, for example, EDS plays a pivotal role in designing modular biosynthetic pathways, constructing artificial chromosomes, and developing novel bio-based materials. Meanwhile, in genetic engineering, the use of enzymatic synthesis is streamlining the development of high-performance microbial strains and transgenic plants. As investment in genomics infrastructure and biotech R&D intensifies, particularly in the wake of the COVID-19 pandemic, enzymatic DNA synthesis is positioned as a disruptive enabler across multiple life science verticals.
Regionally, North America leads the global enzymatic DNA synthesis market, bolstered by the presence of early adopters, substantial funding, and cutting-edge research infrastructure. The United States, in particular, is a hub for synthetic biology innovation, home to key players pioneering EDS technology and scaling up its industrial application. Europe follows closely, driven by high levels of academic-industry collaboration and government-sponsored genomic research in countries like the UK, Germany, and France. The Asia Pacific region, meanwhile, is projected to witness the highest growth rate over the forecast period, fueled by rising biotech investments, a thriving startup landscape in synthetic biology, and national genomics initiatives across China, India, and Japan. Latin America and the Middle East & Africa are also showing promising growth trajectories as awareness of genomics and synthetic DNA applications broadens.
Major market player included in this report are:
• DNA Script
• Codex DNA, Inc.
• Twist Bioscience Corporation
• Thermo Fisher Scientific, Inc.
• Agilent Technologies, Inc.
• Integrated DNA Technologies (IDT)
• GenScript Biotech Corporation
• Eurofins Genomics
• Camena Bioscience
• Evonetix Ltd
• Touchlight Genetics Ltd
• Nuclera Nucleics Ltd
• Telesis Bio Inc.
• Ansa Biotechnologies
• Molecular Assemblies, Inc.
The detailed segments and sub-segment of the market are explained below:
By Service
• Oligonucleotide Synthesis
• Gene Synthesis
By Application
• Synthetic Biology
• Genetic Engineering
By End-use
• Academic & Government Research Institutes
• Biotechnology & Pharmaceutical Companies
• Contract Research Organizations
• Others
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global Enzymatic DNA Synthesis Market Executive Summary
1.1. Global Enzymatic DNA Synthesis Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Service
1.3.2. By Application
1.3.3. By End-use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Enzymatic DNA Synthesis Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Enzymatic DNA Synthesis Market Dynamics
3.1. Market Drivers
3.1.1. Escalating Demand for Rapid, High-Fidelity DNA Constructs
3.1.2. Shift Toward Eco-Friendly, Enzyme-Based Synthesis Methods
3.1.3. Rising Investment in Synthetic Biology and Gene Therapy R&D
3.2. Market Challenges
3.2.1. High Initial Development and Deployment Costs
3.2.2. Technical Constraints in Long-Sequence Accuracy
3.3. Market Opportunities
3.3.1. Integration with CRISPR and Automated Biomanufacturing Platforms
3.3.2. Expansion in Emerging Markets and Academic Collaborations
3.3.3. Growth in Demand for On-Demand, In Situ DNA Synthesis
Chapter 4. Global Enzymatic DNA Synthesis Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Porter’s Five Forces Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Enzymatic DNA Synthesis Market Size & Forecasts by Service 2022–2032
5.1. Segment Dashboard
5.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Oligonucleotide Synthesis
5.2.2. Gene Synthesis
Chapter 6. Global Enzymatic DNA Synthesis Market Size & Forecasts by Application 2022–2032
6.1. Segment Dashboard
6.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Synthetic Biology
6.2.2. Genetic Engineering
Chapter 7. Global Enzymatic DNA Synthesis Market Size & Forecasts by End-use 2022–2032
7.1. Segment Dashboard
7.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.2.1. Academic & Government Research Institutes
7.2.2. Biotechnology & Pharmaceutical Companies
7.2.3. Contract Research Organizations
7.2.4. Others
Chapter 8. Global Enzymatic DNA Synthesis Market Size & Forecasts by Region 2022–2032
8.1. North America Market
8.1.1. U.S. Market
8.1.1.1. Service breakdown, 2022–2032
8.1.1.2. Application breakdown, 2022–2032
8.1.2. Canada Market
8.2. Europe Market
8.2.1. UK Market
8.2.2. Germany Market
8.2.3. France Market
8.2.4. Spain Market
8.2.5. Italy Market
8.2.6. Rest of Europe Market
8.3. Asia Pacific Market
8.3.1. China Market
8.3.2. India Market
8.3.3. Japan Market
8.3.4. Australia Market
8.3.5. South Korea Market
8.3.6. Rest of Asia Pacific Market
8.4. Latin America Market
8.4.1. Brazil Market
8.4.2. Mexico Market
8.4.3. Rest of Latin America Market
8.5. Middle East & Africa Market
8.5.1. Saudi Arabia Market
8.5.2. South Africa Market
8.5.3. Rest of Middle East & Africa Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. DNA Script
9.1.2. Codex DNA, Inc.
9.1.3. Twist Bioscience Corporation
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. DNA Script
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Codex DNA, Inc.
9.3.3. Twist Bioscience Corporation
9.3.4. Thermo Fisher Scientific, Inc.
9.3.5. Agilent Technologies, Inc.
9.3.6. Integrated DNA Technologies (IDT)
9.3.7. GenScript Biotech Corporation
9.3.8. Eurofins Genomics
9.3.9. Camena Bioscience
9.3.10. Evonetix Ltd
9.3.11. Touchlight Genetics Ltd
9.3.12. Nuclera Nucleics Ltd
9.3.13. Telesis Bio Inc.
9.3.14. Ansa Biotechnologies
9.3.15. Molecular Assemblies, Inc.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes